

Press Release

Kraig Biocraft Laboratories, Inc. Signs Intellectual Property and Collaborative Research Agreement with the University of Notre Dame

-Expansion of Kraig's Sponsored Research within University Laboratories to Include Development of Technical Textiles, Diagnostics and Platform Technologies-

LANSING, MI - May 8, 2008 -- Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) announced this morning that the Company has just signed a renewal and expansion of its Collaborative Research and Intellectual Property Agreement with the University of Notre Dame. The agreement provides Kraig with exclusive licensing rights for the products and technology developed pursuant to the collaboration. Additionally, the agreement extends and expands the Company's ongoing research and development program in the University's genetic laboratories.

"The sponsored research program with the University of Notre Dame is a continuing success," said Kraig's CEO Kim Thompson, "and has already resulted in two provisional patent filings. Kraig's renewal extends the collaborative research into 2009, and expands the focus of the Company's work to include the development of genetic expression systems. These recombinant DNA technologies have potential applications as pharmaceutical platforms and human diagnostics platforms. Each genetic expression system provides multiple possibilities for highly lucrative opportunities for the Company's technology."

The Company's primary focus will remain on the development of high performance, high tensile strength fibers for the multi-billion dollar technical textile market. However, the collaborative research agreement and university research plan will open up new opportunities for Kraig to develop pharmaceutical and diagnostic applications for its genetic engineering technology. This work will continue in the University under the direction of Dr. Malcolm Fraser, a renowned developer of genetic engineering technologies and a member of Kraig's board of scientific advisors.

Already in 2008, Kraig has been able to announce the filing of a provisional patent application for human diagnostic technologies. The invention was a byproduct of the Company's collaborative research program with the University. "The new research plan announced today is an acknowledgement by the Company that this technology has broad applications as a platform technology. These platforms can potentially service multiple markets including human and animal diagnostics, pharmaceutical platforms and recombinant polymers," said Thompson.

A second provisional patent application was filed by the University earlier this year regarding new gene splicing and genetic engineering technologies. The invention relates to the use of DNA's natural repair mechanisms to facilitate gene splicing. This patent application was also filed pursuant to Kraig's collaborative research agreement.

“We are elated that the successful and productive research and development program with the University of Notre Dame will continue into 2009,” said Thompson. “With the new and expanded research plan now in place, we look forward to a fruitful year. Kraig is truly a proud sponsor of scientific research and technological development within the University of Notre Dame. We want to thank the University for this renewal of our agreement, and for the diligent work of the scientists who are helping Kraig to make the future in pharmaceutical and textile technologies.”

Kraig Biocraft Laboratories is a technology company focused on the development of commercially significant high-performance polymers, technical fibers and diverse platform technologies. Based on proprietary genetic engineering technology, Kraig is working to develop and produce polymers and protein-based materials including Spider Silk.

For more information on Kraig Biocraft Laboratories please visit the Company's web site: <http://www.KraigLabs.com>

An audio interview discussing corporate developments is also available on the website

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "efforts," "foresees," "future", "forecasts," "estimates", "intends," "develop," "researching," "research," "goal," "opportunities," "potential," "possibility," "pursue," "could", "should" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions, marketing strategies, ongoing research, or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products and execute on its marketing plans may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

CONTACT: Kraig Biocraft Laboratories, Inc.
Kim Thompson, CEO
(517) 336-0807
info@KraigLabs.com